Insider Transactions in Q1 2024 at Allogene Therapeutics, Inc. (ALLO)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 14
2024
|
David D Chang President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
53,393
-1.18%
|
$213,572
$4.33 P/Share
|
|
Jan 30
2024
|
Geoffrey M. Parker CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
190
+0.02%
|
$570
$3.6 P/Share
|
|
Jan 25
2024
|
Timothy L. Moore Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
96,600
+25.46%
|
-
|
|
Jan 25
2024
|
David D Chang President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
317,800
+6.58%
|
-
|
|
Jan 25
2024
|
Zachary Roberts EVP of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
140,000
+21.37%
|
-
|
|
Jan 25
2024
|
Arie Belldegrun Director |
BUY
Grant, award, or other acquisition
|
Direct |
211,973
+10.2%
|
-
|
|
Jan 25
2024
|
Geoffrey M. Parker CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
29,400
+3.46%
|
-
|
|
Jan 25
2024
|
Earl Martin Douglas SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
41,800
+8.05%
|
-
|
|
Jan 22
2024
|
Zachary Roberts EVP of R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
24,690
-6.17%
|
$74,070
$3.17 P/Share
|